aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma,
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2 May 12, 2021 08:00 ET | Source: aTyr Pharma, Inc. aTyr Pharma, Inc. San Diego, California, UNITED STATES SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and...
Source: globenewswire.com